Pharmacology of Itraconazole

Introduction/Overview

Itraconazole represents a cornerstone in the systemic management of a broad spectrum of fungal infections. As a synthetic triazole antifungal agent, its development marked a significant advancement over earlier imidazole derivatives, offering enhanced efficacy, a wider antifungal spectrum, and improved tolerability. The clinical relevance of itraconazole is underscored by its utility in treating both common and opportunistic mycoses, which pose considerable morbidity and mortality, particularly in immunocompromised patient populations. Its role extends from first-line therapy for certain endemic fungal diseases to prophylaxis and salvage treatment in hematological malignancies and transplant recipients. A thorough understanding of its pharmacology is essential for optimizing therapeutic outcomes while minimizing the risk of adverse events and clinically significant drug interactions.

Learning Objectives

• Describe the molecular mechanism of action of itraconazole, including its inhibition of fungal cytochrome P450 enzymes and the consequent disruption of ergosterol biosynthesis.
• Outline the key pharmacokinetic properties of itraconazole, including the critical influence of formulation, food, and gastric acidity on its oral absorption, and its extensive metabolism by hepatic CYP3A4.
• Identify the primary clinical indications for itraconazole, distinguishing between its use in superficial, subcutaneous, and systemic fungal infections.
• Analyze the major adverse effect profile of itraconazole, with particular attention to dose-related negative inotropy and hepatotoxicity.
• Evaluate the significant drug interaction potential of itraconazole, focusing on its dual role as a substrate and potent inhibitor of CYP3A4, and apply this knowledge to clinical management.

Classification

Itraconazole is classified within the broader category of systemic antifungal agents. Its primary classification is as an azole antifungal, specifically belonging to the triazole subclass. This distinction from the earlier imidazole antifungals (e.g., ketoconazole, miconazole) is based on its chemical structure, which contains a triazole ring instead of an imidazole ring. The triazole moiety confers greater specificity for fungal cytochrome P450 enzymes, contributing to a more favorable safety profile and reduced endocrine side effects compared to some imidazoles.

From a chemical perspective, itraconazole is a cis-triazole derivative, characterized by a complex lipophilic structure that includes a dioxolane ring. This lipophilicity is a fundamental determinant of its pharmacokinetic behavior, influencing its high volume of distribution, tissue penetration, and extensive protein binding. Therapeutically, itraconazole is considered a broad-spectrum antifungal, with activity against dermatophytes, yeasts (including some Candida species), and a variety of filamentous and dimorphic fungi. It is not considered a first-line agent for invasive candidiasis or cryptococcosis but holds particular importance in the management of aspergillosis, blastomycosis, histoplasmosis, and certain dermatophytic infections.

Mechanism of Action

The antifungal activity of itraconazole, like other azoles, is primarily mediated through the inhibition of ergosterol biosynthesis, a critical component of the fungal cell membrane.

Molecular and Cellular Mechanisms

The primary molecular target of itraconazole is lanosterol 14α-demethylase, a cytochrome P450-dependent enzyme (encoded by the ERG11 gene in yeast). This enzyme catalyzes the oxidative removal of the 14α-methyl group from lanosterol, a key step in the conversion of lanosterol to ergosterol. Itraconazole binds to the heme iron atom located in the active site of this fungal cytochrome P450 enzyme, acting as a non-competitive inhibitor. The binding is facilitated by the unhindered nitrogen atom in the triazole ring, which coordinates with the heme iron, preventing the enzyme from binding its natural substrate and molecular oxygen.

The inhibition of lanosterol 14α-demethylase leads to the accumulation of 14α-methylated sterol precursors (e.g., lanosterol, 24-methylenedihydrolanosterol) and a concurrent depletion of ergosterol in the fungal cell membrane. Ergosterol serves multiple vital functions: it is the principal sterol providing structural integrity and fluidity to the membrane, and it is essential for the proper function of membrane-bound enzymes, including those involved in cell wall synthesis. The incorporation of aberrant methylated sterols into the membrane disrupts its architecture and function. Consequences include increased membrane permeability, disruption of electron transport chains, and inhibition of fungal cell growth and replication. At higher concentrations, itraconazole may exert fungicidal activity against some organisms, potentially through more profound membrane disruption or secondary effects on chitin synthesis.

Spectrum of Activity

The spectrum of activity is broad but not uniform. Itraconazole demonstrates potent activity against most Aspergillus species, Blastomyces dermatitidis, Histoplasma capsulatum, Coccidioides immitis/posadasii, Sporothrix schenckii, and many dermatophytes (Trichophyton, Microsporum, Epidermophyton). Its activity against Candida species is variable, being more reliable against C. albicans and C. parapsilosis than against C. glabrata or C. krusei. It has limited or no activity against Zygomycetes (e.g., Mucor, Rhizopus), Fusarium species, and Scedosporium apiospermum.

Pharmacokinetics

The pharmacokinetic profile of itraconazole is complex, characterized by highly variable absorption, extensive tissue distribution, and metabolism dominated by hepatic cytochrome P450 enzymes.

Absorption

Oral absorption of itraconazole is incomplete and highly dependent on formulation, gastric pH, and the presence of food. The original capsule formulation requires an acidic gastric environment for dissolution. Absorption is significantly enhanced when the capsule is taken with a full meal or an acidic beverage, which can increase bioavailability by up to 200% compared to the fasting state. Concomitant use of agents that reduce gastric acidity, such as proton pump inhibitors, H₂-receptor antagonists, and antacids, can severely impair absorption. An oral solution formulation, which uses a hydroxypropyl-β-cyclodextrin solubilizer, exhibits less dependency on gastric acidity and food, though its bioavailability is still improved by fasting conditions. The absolute bioavailability of the capsule is approximately 55% when taken with food, while the solution’s bioavailability under fasting conditions is higher. After oral administration, peak plasma concentrations (C_max) are typically achieved within 2 to 5 hours.

Distribution

Itraconazole is highly lipophilic and extensively bound to plasma proteins (>99.8%), primarily albumin. It demonstrates a large volume of distribution (V_d > 10 L/kg), indicating extensive penetration into tissues. Concentrations in tissues such as lung, kidney, liver, bone, and skin can be several-fold higher than concurrent plasma concentrations. It also penetrates well into abscesses, nails, and bronchial secretions. Notably, itraconazole penetrates poorly into the cerebrospinal fluid and aqueous humor, limiting its utility in fungal meningitis or endophthalmitis without adjunctive therapy. The active hydroxy-itraconazole metabolite exhibits a similar distribution profile.

Metabolism

Itraconazole undergoes extensive first-pass and systemic metabolism in the liver. The primary metabolic pathway is oxidation, catalyzed predominantly by the cytochrome P450 3A4 (CYP3A4) isoenzyme. The major metabolite is hydroxy-itraconazole, which possesses antifungal activity comparable to the parent compound and circulates at plasma concentrations approximately twice that of itraconazole. This metabolite contributes significantly to the overall therapeutic effect. Further metabolism yields a large number of inactive metabolites. Itraconazole and its metabolites do not induce their own metabolism.

Excretion

Elimination is primarily hepatic. Following oral administration of radiolabeled drug, approximately 35-54% of the dose is excreted in the feces as unchanged drug and metabolites over one week. Renal excretion of unchanged itraconazole and the active metabolite is negligible (<0.03% of the dose). The terminal elimination half-life (t_1/2) is dose-dependent and ranges from 24 to 42 hours following a single dose. With multiple dosing, steady-state concentrations are generally achieved within 10 to 14 days. The long half-life supports once- or twice-daily dosing regimens after an initial loading dose is administered to achieve therapeutic concentrations more rapidly.

Therapeutic Uses/Clinical Applications

Itraconazole is indicated for the treatment of a wide array of fungal infections. Its use is guided by the infecting organism, site of infection, immune status of the host, and local resistance patterns.

Approved Indications

• Blastomycosis: Used for pulmonary and non-meningeal disseminated disease in immunocompetent patients. Often considered a first-line oral agent.
• Histoplasmosis: Effective for chronic pulmonary and disseminated non-meningeal histoplasmosis, including maintenance therapy to prevent relapse in patients with AIDS.
• Aspergillosis: Indicated for pulmonary and extrapulmonary aspergillosis in patients who are intolerant of or refractory to amphotericin B therapy. It is not a first-line agent for invasive aspergillosis but remains important in certain chronic or allergic forms (e.g., allergic bronchopulmonary aspergillosis).
• Onychomycosis: Used for dermatophyte infections of the fingernails and toenails due to its excellent keratin affinity and persistence in the nail plate. Pulse dosing regimens are commonly employed.
• Systemic and Dermatophytic Infections: For severe systemic infections caused by susceptible fungi and for extensive dermatophytoses (tinea corporis, tinea cruris, tinea pedis) that are unresponsive to topical therapy.
• Oral and Esophageal Candidiasis: The oral solution is indicated for oropharyngeal and esophageal candidiasis, particularly in immunocompromised patients.

Off-Label Uses

Several off-label applications are supported by clinical evidence and guidelines. These include treatment of sporotrichosis (lymphocutaneous and fixed cutaneous forms), chromoblastomycosis, paracoccidioidomycosis, and certain forms of coccidioidomycosis (non-meningeal). It is also used for prophylaxis against invasive fungal infections in high-risk patients with prolonged neutropenia, such as those undergoing chemotherapy for hematologic malignancies. Furthermore, itraconazole has been investigated for its potential antiangiogenic and hedgehog signaling pathway inhibitory effects in oncology, though this is not a standard therapeutic application.

Adverse Effects

The tolerability profile of itraconazole is generally favorable compared to older systemic antifungals like amphotericin B, but significant adverse effects necessitate vigilant monitoring.

Common Side Effects

Gastrointestinal disturbances are most frequently reported and include nausea, vomiting, diarrhea, abdominal pain, and dyspepsia. These effects are often more common with the oral solution than the capsule. Other common adverse reactions involve the nervous system (headache, dizziness) and skin (rash, pruritus). Transient, asymptomatic elevations in liver enzymes (alanine aminotransferase, aspartate aminotransferase) are observed in a notable minority of patients.

Serious and Rare Adverse Reactions

• Hepatotoxicity: Symptomatic hepatitis, cholestasis, and fulminant hepatic failure, while rare, have been reported. Liver function tests are recommended prior to and periodically during treatment courses exceeding one month.
• Cardiac Effects: A dose-related negative inotropic effect has been documented. Itraconazole can depress left ventricular ejection fraction and has been associated with cases of congestive heart failure, particularly in patients with pre-existing cardiac disease or those receiving high cumulative doses. It is contraindicated in patients with evidence of ventricular dysfunction.
• Hypokalemia: May occur, especially with high doses or prolonged therapy, due to an effect on renal tubular ion transport.
• Peripheral Neuropathy: A rare association has been noted.
• Stevens-Johnson Syndrome: Severe cutaneous adverse reactions are exceedingly rare.

No black box warnings are currently mandated by regulatory agencies for itraconazole, but the potential for serious hepatotoxicity and congestive heart failure is prominently highlighted in prescribing information.

Drug Interactions

Itraconazole presents a high potential for clinically significant drug interactions due to its potent inhibition of CYP3A4 and its own metabolism by this enzyme. These interactions can lead to either toxic elevations of concomitant drugs or subtherapeutic levels of itraconazole.

Major Drug-Drug Interactions

As a potent inhibitor of CYP3A4, itraconazole can dramatically increase the plasma concentrations of drugs that are metabolized by this pathway, potentially leading to serious toxicity. Key contraindicated or strongly discouraged combinations include:

• QTc-Prolonging Agents: Concomitant use with drugs metabolized by CYP3A4 that also prolong the QTc interval (e.g., quinidine, dofetilide, pimozide) is contraindicated due to the high risk of life-threatening ventricular arrhythmias, including torsades de pointes.
• HMG-CoA Reductase Inhibitors (Statins): Particularly simvastatin and lovastatin, which are extensively metabolized by CYP3A4. Coadministration can lead to a marked increase in statin exposure and a heightened risk of rhabdomyolysis.
• Benzodiazepines: Midazolam and triazolam levels are significantly increased, potentiating and prolonging sedative effects; oral administration of these benzodiazepines is contraindicated.
• Ergot Alkaloids: Dihydroergotamine and ergotamine are contraindicated due to the risk of severe vasospasm and ischemia.
• Immunosuppressants: Concentrations of cyclosporine, tacrolimus, and sirolimus can be significantly elevated, necessitating close therapeutic drug monitoring and dose reduction.
• Others: Significant interactions requiring dose adjustment or avoidance include those with warfarin (increased INR), digoxin (increased digoxin levels), certain calcium channel blockers, and protease inhibitors used in HIV therapy.

Conversely, drugs that induce CYP3A4 (e.g., rifampin, rifabutin, phenytoin, carbamazepine, phenobarbital) can substantially reduce itraconazole plasma concentrations, leading to therapeutic failure. Rifampin can reduce itraconazole AUC by over 90%. Drugs that reduce gastric acidity (PPIs, H₂ antagonists) can impair absorption of the capsule formulation.

Contraindications

Itraconazole is contraindicated for the treatment of onychomycosis or dermatophytoses in patients with evidence of ventricular dysfunction such as congestive heart failure (CHF) or a history of CHF. It is also contraindicated in patients with known hypersensitivity to itraconazole or any component of its formulation. Coadministration with the specific drugs mentioned above (e.g., quinidine, pimozide, oral midazolam, ergot alkaloids, simvastatin, lovastatin) is contraindicated.

Special Considerations

Pregnancy and Lactation

Itraconazole is classified as Pregnancy Category C. Animal studies have demonstrated embryotoxicity and teratogenicity at high doses. Adequate and well-controlled studies in pregnant women are lacking. Use during pregnancy is generally not recommended, especially for non-life-threatening conditions like onychomycosis, and should be reserved for serious systemic fungal infections where the potential benefit justifies the potential fetal risk. Itraconazole is excreted in human breast milk. Due to the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug.

Pediatric and Geriatric Considerations

Safety and effectiveness in pediatric patients have not been fully established for all indications, though it is used in children for certain systemic fungal infections. Dosing is typically based on body weight. In elderly patients, no overall differences in safety or efficacy have been observed, but greater sensitivity due to age-related decreases in hepatic, renal, or cardiac function is possible, warranting caution.

Renal and Hepatic Impairment

Renal impairment does not significantly affect the pharmacokinetics of itraconazole, as renal excretion is minimal. Dose adjustment is not routinely required. However, the cyclodextrin vehicle in the intravenous formulation accumulates in renal failure and is not recommended for patients with a creatinine clearance below 30 mL/min. Hepatic impairment is a critical consideration. Itraconazole is extensively metabolized in the liver. In patients with cirrhosis or other forms of hepatic impairment, bioavailability may be increased and metabolism decreased, leading to significantly elevated drug exposure. Use in patients with elevated liver enzymes or active liver disease is not recommended unless the benefit clearly outweighs the risk. If treatment is necessary, monitoring of liver function is essential, and dose reduction may be required.

Summary/Key Points

• Itraconazole is a broad-spectrum triazole antifungal whose mechanism of action involves inhibition of fungal lanosterol 14α-demethylase, disrupting ergosterol synthesis and compromising cell membrane integrity.
• Oral bioavailability is highly variable and dependent on formulation, gastric pH, and food. The capsule requires an acidic environment and a fatty meal for optimal absorption, while the solution is less dependent on acidity.
• Pharmacokinetically, itraconazole is characterized by high protein binding, extensive tissue distribution (except CSF), and metabolism primarily via hepatic CYP3A4 to an active hydroxy-metabolite.
• Major clinical indications include blastomycosis, histoplasmosis, aspergillosis (in selected cases), onychomycosis, and oropharyngeal/esophageal candidiasis (solution).
• The most significant adverse effects involve the liver (hepatotoxicity) and heart (dose-related negative inotropy and risk of congestive heart failure).
• Itraconazole is a potent inhibitor of CYP3A4 and is itself a substrate, resulting in a high potential for numerous and serious drug-drug interactions. Coadministration with QTc-prolonging agents, certain statins, and specific benzodiazepines is contraindicated.
• Use in patients with hepatic impairment requires extreme caution and close monitoring. It is not recommended during pregnancy or lactation for non-serious conditions.

Clinical Pearls

• Always verify the formulation prescribed. Counsel patients to take the capsule with a full meal and to avoid concurrent use of acid-reducing agents. The oral solution should be taken on an empty stomach.
• Consider a loading dose (e.g., 200 mg three times daily for 3 days) to achieve steady-state therapeutic concentrations more rapidly when treating systemic infections.
• Routine monitoring of liver function tests is advised for treatment durations exceeding one month.
• Assess cardiac status, including a review of symptoms and potentially an echocardiogram, in patients with a history of cardiac disease or those who will receive high-dose or prolonged therapy.
• Maintain a high index of suspicion for drug interactions. A thorough medication reconciliation, including over-the-counter and herbal products, is mandatory prior to initiating therapy.
• Therapeutic drug monitoring of itraconazole plasma concentrations may be considered in severe infections, when managing complex drug interactions, or when clinical response is suboptimal despite appropriate dosing.

References

1. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
2. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
3. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
4. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
5. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
6. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
7. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
8. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.